Regenerative orthobiologic medical devices for patients
We call it biotherapeutic excellence
As leading cell matrix specialists, we specialise in exceptional collagen technology for the treatment of cartilage defects in joints. Our over 30 years of experience is delivered by a highly-motivated team of qualified experts with excellent scientific knowledge and a broad basis of expertise in the field. We aim to go the extra mile and surpass expectations so that we can offer innovative biotherapeutic solutions to our customers in the medical and healthcare sectors and to all of our patients. Cartilage regeneration in joints is what we do. And our philosophy is to restore and preserve quality of life – and keep you moving.
Innovative biomedicine from Esslingen/Germany:
meidrix biomedicals is a leading pioneer in the field of cartilage regeneration on the basis of native, ultrapure collagen.
The innovative biomedicine company from Esslingen in Baden-Württemberg/Germany launched its first acellular collagen implant for treatment of joint cartilage damage in 2013 with its product ChondroFillerGel. 2013 saw the launch of a new generation of implant technology for cartilage regeneration with the product innovation ChondroFiller®. The world’s first implant made of collagen that is applied in liquid form and solidifies directly in the cartilage defect after arthroscopic implantation was licensed for market readiness. The patented ChondroFiller® implant stimulates the body to convert the offered matrix and to form its own cartilage tissue.
Unlike with other methods for treatment of joint cartilage damage, this offers a number of advantages. Firstly, only a single surgical procedure is required, and no healthy cartilage needs to be damaged through removal of a biopsy. The bone remains undamaged during the treatment, and the regenerated cartilage material is similar to the natural cartilage generated in the body. As a result, this treatment method is particularly gentle, effective and inexpensive, and it enables orthopaedic doctors to provide long-term treatment for clearly localised damage to the joint cartilage.
Our history: science for orthopaedic practice
The technology behind ChondroFiller® goes back to scientist and company founder Dr. Thomas Graeve.
For many years, Dr. Graeve researched collagen products together with Dr. Michaela Noll as the head of the Cell Systems department at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart. In 2009 he founded Amedrix GmbH in order to revolutionise the treatment of joint cartilage with the company until his early death in 2017. Important milestones included the licensing of ChondroFillerGel in 2012 and ChondroFiller® liquid in 2013. In orthopaedic practice, the further development of ChondroFiller® liquid proved so successful that it replaced the gel version of the product in the meantime. While the gel needed to be individually trimmed to size for implantation in the patient, this step is no longer required with the product that is applied in liquid form. meidrix has 2 patents for liquid application of collagen.
“With ChondroFiller® we have made the natural regeneration of joints our mission, so that we can preserve mobility and quality of life”.
Dr. Michaela Noll (CEO)
We work continuously to unlock new milestones together with our partners
2022
2021
Recertification by new approval body – marketing authorisation granted for ChondroFiller® in India
Surgeons in China start using ChondroFiller®
2020
Expansion
2018
Foundation of meidrix biomedicals GmbH
Acquisition of previous Amedrix GmbH by a new principal investor
2013
CE certification / marketing authorisation granted for ChondroFiller® liquid
2012
2009
The high-tech start-up fund and the life science fund Esslingen invest a total of EUR 700,000 Euro in the newly established company
Seit 1990
We are experts in top-quality collagen products
We have developed ChondroFiller® with our team of doctors and scientists in close collaboration with the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart.
Our collagen implants for liquid application in joint cartilage defects using a two-chamber syringe are manufactured in accordance with strictest quality standards in a state-of-the-art production facility. In addition, we also offer high-quality collagen products for research & development.
Certification
We are certified in accordance with ISO EN 13485 for medical devices; 93/42/EEC, Annex II, excluding section 4; 93/42/EEC, Annex II, section 4; DIN EN ISO 9001.
